Sorry to hear that Scout. I believe the rising stock price on moderate volume in recnt weeks is reflecting the future (early 2018) share price gains from the imminent news flow on Nant's advanced Cancer trial which can attract non-dilutive capital anytime from Patrick Soon-Shiong and reach milestones much sooner than any of the other programs including AMD. We cannot afford to be sentimental or dwell on the past. The future of this company is Oncology.
Good things happen when we are not expecting them. Its always darkest before the storm. The most spectacular gains in markets are made from the lowest base or inflection point. We are on the cusp of this change now.
CC, page-32
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)